Literature DB >> 9721032

Characterization of endomorphin-1 and -2 on [35S]GTPgammaS binding in the mouse spinal cord.

M Narita1, H Mizoguchi, G S Oji, E L Tseng, C Suganuma, H Nagase, L F Tseng.   

Abstract

In the present study, G-protein activation by newly-isolated opioid peptides, endomorphin-1 and -2, was examined in the mouse spinal cord by monitoring the binding of the non-hydrolyzable analog of GTP, guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS). Both endomorphin-1 and -2 increased [35S]GTPgammaS binding to mouse spinal cord membranes in a concentration-dependent and saturable manner and reached a maximal stimulation of 57.3+/-5.0 and 60.2+/-3.2%, respectively, at 10 microM. In contrast, the synthetic selective micro-opioid receptor agonist [D-Ala2,NHPhe4,Gly-ol]enkephalin (DAMGO) had a much greater efficacy and produced 103.4+/-5.4% of the maximal stimulation. The receptor specificity of endomorphin-stimulated [35S]GTPgammaS binding was verified by co-incubating membranes with endomorphins in the presence of specific micro-(beta-funaltrexamine and D-Phe-Cys-D-Tyr-Om-Thr-Pen-Thr-NH2 (CTOP)), delta-(naltrindole) or K-(nor-binaltorphimine) opioid receptor antagonists. Co-incubation with either beta-funaltrexamine or CTOP blocked both endomorphin-1- and-2-stimulated [35S]GTPgammaS binding in a concentration-dependent manner, whereas neither naltrindole nor nor-binaltorphimine had any effect on the [35S]GTPgammaS binding stimulated by either endomorphin-1 or -2. The data presented indicate that either endomorphin-1 or -2 activate G-proteins by specific stimulation of micro-opioid receptors, and may act as partial agonists with moderate catalytic efficacies in the mouse spinal cord.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721032     DOI: 10.1016/s0014-2999(98)00395-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.

Authors:  M Narita; H Mizoguchi; D E Oji; N J Dun; B H Hwang; H Nagase; L F Tseng
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1.

Authors:  M G Paterlini; F Avitabile; B G Ostrowski; D M Ferguson; P S Portoghese
Journal:  Biophys J       Date:  2000-02       Impact factor: 4.033

3.  Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior.

Authors:  K Sinchak; P E Micevych
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

4.  Endomorphin-2: a biased agonist at the μ-opioid receptor.

Authors:  Guadalupe Rivero; Javier Llorente; Jamie McPherson; Alex Cooke; Stuart J Mundell; Craig A McArdle; Elizabeth M Rosethorne; Steven J Charlton; Cornelius Krasel; Christopher P Bailey; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2012-05-02       Impact factor: 4.436

5.  Mu-opioid receptor modulation of calcium channel current in periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR-1.

Authors:  M Connor; A Schuller; J E Pintar; M J Christie
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

6.  Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.

Authors:  M Narita; H Mizoguchi; M Narita; I Sora; G R Uhl; L F Tseng
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.

Authors:  Hong Xie; James H Woods; John R Traynor; Mei-Chuan Ko
Journal:  Anesth Analg       Date:  2008-06       Impact factor: 5.108

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.